라임병 검사 시장 기회, 성장 촉진 요인, 산업 동향 분석, 예측(2025-2034년)

The Global Lyme Disease Testing Market is expected to reach USD 6.7 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2034. This growth is primarily driven by the increasing prevalence of Lyme disease in regions like North America and parts of Europe, where the infection is most common. Rising awareness of the serious long-term effects of untreated Lyme disease, such as neurological and musculoskeletal complications, has fueled the demand for early diagnosis and prompt treatment, further expanding the market.

Significant advancements in diagnostic technologies, including the widespread adoption of point-of-care (POC) tests and at-home testing kits, are reshaping the market. These innovative solutions offer quick and convenient diagnostic options that promote early detection and intervention, encouraging individuals to take action sooner. Public health initiatives and educational campaigns supported by government and health organizations have been crucial in raising awareness and advocating for regular testing. Additionally, the growing funding for research on tick-borne diseases is driving innovation and fueling further growth within the market.

In terms of diagnostic technology, the market is divided into several segments, including serological tests, nucleic acid tests, lymphocytic transformation tests, urine antigen testing, and immunofluorescent staining. The serological test segment is poised to experience the highest growth, with a projected CAGR of 6.2%, generating USD 5 billion by 2034. This growth is primarily attributed to the increasing adoption of serological tests, driven by technological advancements that have enhanced their reliability and effectiveness. Tests such as enzyme-linked immunosorbent assay (ELISA) and Western blot are highly effective at detecting Borrelia burgdorferi antibodies, securing their position as the most widely used and trusted method for Lyme disease detection.

The market is also categorized by sample type, including blood, urine, cerebrospinal fluid (CSF), and other blood-based samples. In 2024, the blood sample segment accounted for a 52.2% share of the market and is expected to maintain its dominant position throughout the forecast period. Blood samples are considered the gold standard for Lyme disease testing due to their high accuracy in detecting both antibodies and bacterial DNA. This makes them the preferred choice in clinical and laboratory settings, offering a simple and non-invasive diagnostic method.

In the U.S., the Lyme disease testing market, valued at USD 2.6 billion in 2024, is poised for strong growth during the forecast period. The high incidence of Lyme disease, combined with its geographical spread due to climate change and increased tick activity, is driving demand for testing services. Growing public awareness, supported by health organizations, is encouraging more proactive approaches to Lyme disease screening. As a result, healthcare providers are increasingly prioritizing Lyme disease testing, especially in high-risk areas, contributing to sustained market growth in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of Lyme disease
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Rising adoption of at-home test kits
    • 3.2.1.4 Growth in point-of-care testing
    • 3.2.1.5 Integration of artificial intelligence (AI)
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced diagnostic tests
    • 3.2.2.2 Lack of standardized testing guidelines
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Diagnostic Technology, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Serological test
  • 5.2.1 ELISA
  • 5.2.2 Western blot
• 5.3 Nucleic acid test
• 5.4 Urine antigen testing
• 5.5 Lymphocytic transformation test
• 5.6 Immunofluorescent staining

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Blood
• 6.3 Urine
• 6.4 CSF
• 6.5 Other blood samples

Chapter 7 Market Estimates and Forecast, By Patient Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Adult
• 7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic laboratories
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 bioMérieux
• 10.2 Bio-Rad Laboratories
• 10.3 Ceres Nanosciences
• 10.4 DiaSorin
• 10.5 Galaxy Diagnostics
• 10.6 Gold Standard Diagnostics
• 10.7 IGeneX
• 10.8 Oxford Immunotec
• 10.9 T2 Biosystems
• 10.10 Thermo Fisher Scientific
• 10.11 Trinity Biotech
• 10.12 ZEUS Scientific